Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned an average recommendation of “Hold” from the thirteen brokerages that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $376.30.

MEDP has been the topic of several recent analyst reports. Leerink Partners started coverage on shares of Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Leerink Partnrs upgraded Medpace to a “hold” rating in a report on Monday. Finally, Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th.

Medpace Stock Performance

NASDAQ:MEDP opened at $316.61 on Friday. The stock has a 50 day moving average price of $336.40 and a 200 day moving average price of $339.26. The stock has a market cap of $9.65 billion, a PE ratio of 25.07, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace has a one year low of $302.01 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently bought and sold shares of MEDP. Lindbrook Capital LLC increased its stake in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC lifted its holdings in Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock worth $1,789,000 after buying an additional 29 shares in the last quarter. Assetmark Inc. lifted its holdings in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after buying an additional 29 shares in the last quarter. Proficio Capital Partners LLC boosted its position in Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after buying an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. increased its position in shares of Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after acquiring an additional 30 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.